SLC5A2 and Obesity: Obesity is a well-established driver of insulin resistance and cardiorenal risk, and SGLT2 inhibitors exert multiple favorable metabolic effects—including weight loss, blood pressure reduction, and natriuresis—that may be especially beneficial in this population.